Mayo Clinic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mayo Clinic sits in the top decile of US sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count).
Mayo Clinic: 2,844 sponsored US clinical trials, 544 recruiting.
Mayo Clinic sponsors 2,844 registered US clinical trials on ClinicalTrials.gov, 544 of them currently recruiting, and 1,816 completed. 252 of these trials are in Phase 3-4 (later-stage) and 821 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 36 trials.
Top-decile sponsor footprint
Mayo Clinic ranks in the top decile of sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,844 total, page 7 of 57
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT06205316
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
NCT06065436
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
NCT05917145
Adipose Tissue Blood Flow in Aging Humans
NCT06096532
Breathing Training and Exercise Capacity in Non-CFB
NCT05860803
A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
NCT06006884
Rapid Rehabilitation to Treat Lower Extremity Trauma
NCT05225792
Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer
NCT06246955
MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
NCT06274034
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
NCT06508463
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
NCT06151730
Metabolic and Physiologic Responses to Hormone Therapy in Transgender and Gender Diverse People
NCT06083766
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
NCT05847569
A Study of Pulmonary Hypertension Peripheral Limitations
NCT05968859
A Study of Niacin Regulation
NCT06175403
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
NCT06416969
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
NCT06104618
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT06153836
A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers
NCT05739149
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
NCT05802056
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
NCT06078709
iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men
NCT06535802
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
NCT06122064
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
NCT05976165
Accelerated Resolution Therapy for Early Maladaptive Grief
NCT05624879
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
NCT06557057
Disparities Among Liver Transplant Patients
NCT05981196
A Study of Glycemic Control in Left Ventricular Assist
NCT05933161
The Effect of Synaquell™ in Contact Sport Athletes
NCT06104670
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
NCT06600659
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
NCT06055881
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
NCT06028022
Using Facebook to Support Opioid Recovery Among American Indian Women
NCT05995886
A Study of Invasive Hemodynamic for MACHD Registry
NCT05849025
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
NCT06071845
INTERogating Cancer for Etiology, Prevention and Therapy Navigation
NCT06008392
Cardiac Rehabilitation Mobile-Health Fall Risk Prevention Intervention
NCT05826587
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
NCT05109208
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
NCT05717153
Beetroot Juice and Sleep
NCT05864521
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT05920798
Exercise Response in Humans With Obesity
NCT05857150
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
NCT05739162
Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction
NCT05854303
A Study of TopSpin360 Training Device
NCT06052553
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT05969860
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
NCT05654506
A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures
NCT05806996
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis
NCT05992883
Pulmonary Hypertension in Left Heart Disease
NCT05935605
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 435 |
| Phase 2 | 386 |
| Phase 3 | 86 |
| Phase 4 | 166 |
Therapeutic Areas
What is open in the Mayo Clinic pipeline
544 recruiting of 2,844 indexed (19% open); 1,816 completed (64%).
Phase mix: 252 late (III/IV) vs 821 early (I/II) (early-phase heavy).
Top condition: Healthy (36 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.